Cancer CAR T cells rally immunity against tumors, so a Lausanne team flipped the same engineering to suppress the allergic asthma over reaction in mice, with birch pollen as the test case.
The same cell-engineering trick that put chimeric antigen receptor T cells, or CAR-T, into cancer clinics can be turned inside out: instead of building a T cell that hunts tumors, build a T cell that brakes the immune over-reaction behind an allergy. A peer-reviewed mouse study from a Lausanne team shows the inversion works, at least against birch pollen, and lays the groundwork for a cell-therapy platform aimed at the most vulnerable slice of asthma patients.
The work, published in the Journal of Experimental Medicine, comes from Lausanne University Hospital, the University of Lausanne, and the Center for Human Immunology Lausanne. Lead investigator Yannick D. Muller, MD, PhD, an associate professor at Lausanne University Hospital, told GenEng News that "our study provides proof-of-concept and preclinical evidence that CAlleR Tregs redirected against a birch pollen allergen can downmodulate birch pollen–induced allergic asthma."
Roughly 300 million people live with asthma worldwide, and around 60% of those cases are allergic asthma, where a type 2 immune over-reaction floods the airways with IL-4, IL-5, and IL-13 cytokines, drives mucus plugging, and in severe cases kills. The only disease-modifying option today is allergen immunotherapy, a course of gradually escalating doses. "Allergen immunotherapy is not recommended for patients with severe asthma, representing the most vulnerable population at greatest risk of asthma-related morbidities and mortality," Muller told GenEng News. That gap is what makes the Lausanne result worth watching.
The engineer's move was to take regulatory T cells, the immune system's own brakes, and arm them with a chimeric receptor that recognizes a specific allergen. The cells, called CAlleR Tregs for chimeric allergen receptor regulatory T cells, behave like traffic cops recruited to the site of an allergic trigger, damping inflammation on contact. The platform borrows its architecture directly from CAR-T: a synthetic receptor, an antibody-derived recognition piece, and intracellular signaling domains that fire when the receptor finds its target. The difference is direction. Where CAR-T amplifies, CAlleR Tregs suppress.
Muller and colleagues built their receptor around Bet v 1, the dominant birch pollen allergen that sensitizes an estimated 8–16% of Europeans. They started with four anti-birch antibodies isolated from an allergic patient, pulled out each antibody's targeting tip as a single-chain variable fragment (scFv), and fused it to a CD28-ζ intracellular signaling domain that activates the Treg when the receptor binds its target. A surprise in the data: the engineered Tregs suppressed best when a non-competing antibody bound the allergen at the same time, suggesting receptor cross-linking is what flips the cells into active suppression. That mechanism, the authors wrote in JEM, "opens new avenues not only for rewiring synthetic receptors against any soluble antigens including autoantigens for therapeutic intervention but also for delineating a more global pathway for antigen cross-presentation in allergies."
The mouse experiments came in two flavors. In one, CAlleR Tregs were infused into mice already sensitized to birch pollen; on re-exposure, treated animals showed less airway inflammation, less mucus, and better lung function. In the other, the cells were infused into naive mice before any pollen exposure, and those animals failed to develop asthma symptoms at all. The team frames both results as prevention and treatment candidates, not as efficacy in people.
The honest read is more modest. This is one paper, one allergen, one species. Allergic-airway inflammation in mice is a model with a long record of imperfect translation, and engineered Treg products will inherit the manufacturing, dosing, durability, and safety questions that have shadowed cell therapies; the broader CAR-T experience is the standing reminder that engineered immune cells can carry serious off-target risks. Muller told GenEng News that "future studies should evaluate the persistence and stability of CAlleR Tregs over time and define the optimal modalities for implementing such a therapeutic approach."
The authors also float a wider target list: CAlleRs against house dust mites, food allergens, and other soluble antigens, a family of conditions where restoring tolerance is the missing therapeutic lever. None of that is in the present study. The present study is the platform's first peer-reviewed demonstration that the cancer-immunotherapy engineering playbook can be turned, structurally, from immune amplifier to immune brake. A preprint of the work is also available on Research Square and indexed in Sciety's activity feed, with broader aggregator coverage at Mirage News that re-reports the same finding under a "breakthrough" frame the underlying paper does not support.
The next milestone to watch is whether the Lausanne group, or anyone building on the platform, can move CAlleR Tregs into a non-human primate or first-in-human study that keeps the antigen specificity and adds a credible durability readout. Until then, the inversion is real on paper and in mice, and the bridge to severe allergic-asthma patients is still unmapped.